tiprankstipranks
Trending News
More News >

Keros Therapeutics Announces Major Workforce Reduction Plan

Story Highlights
  • Keros Therapeutics plans to cut its workforce by 45% to align with strategic priorities.
  • The company discontinued cibotercept development in PAH after safety concerns in the TROPOS trial.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
Keros Therapeutics Announces Major Workforce Reduction Plan

Confident Investing Starts Here:

Keros Therapeutics ( (KROS) ) has provided an announcement.

On May 28, 2025, Keros Therapeutics‘ Board of Directors approved a plan to reduce the company’s workforce by approximately 45%, aiming to align operations with strategic priorities and achieve cost savings. This reorganization, expected to be completed by the fourth quarter of 2025, follows the discontinuation of cibotercept development in pulmonary arterial hypertension due to safety concerns observed in the TROPOS trial. The company is evaluating strategic alternatives, including potential business transactions, to maximize shareholder value.

The most recent analyst rating on (KROS) stock is a Buy with a $100.00 price target. To see the full list of analyst forecasts on Keros Therapeutics stock, see the KROS Stock Forecast page.

Spark’s Take on KROS Stock

According to Spark, TipRanks’ AI Analyst, KROS is a Neutral.

Keros Therapeutics is in a growth phase with strong revenue increases but significant unprofitability typical of biotech firms. The balance sheet is strong, but the company relies heavily on external financing. Technical indicators show short-term positive momentum, while valuation remains challenging due to negative earnings.

To see Spark’s full report on KROS stock, click here.

More about Keros Therapeutics

Keros Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics for disorders linked to dysfunctional signaling of the TGF-ß family of proteins. The company is a leader in understanding the role of these proteins, which are crucial for the growth, repair, and maintenance of various tissues. Keros is developing protein therapeutics with the potential to provide significant benefits to patients, with lead product candidates targeting neuromuscular diseases and cytopenias.

Average Trading Volume: 1,007,195

Technical Sentiment Signal: Sell

Current Market Cap: $582.8M

Find detailed analytics on KROS stock on TipRanks’ Stock Analysis page.

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.

Report an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App